Graham Capital Management L.P. Has $664,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Graham Capital Management L.P. cut its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 50.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,139 shares of the company's stock after selling 10,259 shares during the quarter. Graham Capital Management L.P.'s holdings in AstraZeneca were worth $664,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of AZN. Focus Partners Wealth lifted its stake in shares of AstraZeneca by 9.1% in the fourth quarter. Focus Partners Wealth now owns 69,067 shares of the company's stock valued at $4,589,000 after buying an additional 5,760 shares during the period. Ethic Inc. increased its holdings in shares of AstraZeneca by 7.1% during the fourth quarter. Ethic Inc. now owns 97,608 shares of the company's stock worth $6,395,000 after buying an additional 6,475 shares in the last quarter. Fiduciary Trust Co increased its holdings in shares of AstraZeneca by 56.2% during the fourth quarter. Fiduciary Trust Co now owns 11,223 shares of the company's stock worth $735,000 after buying an additional 4,039 shares in the last quarter. Clark Capital Management Group Inc. increased its holdings in shares of AstraZeneca by 89.2% during the fourth quarter. Clark Capital Management Group Inc. now owns 10,047 shares of the company's stock worth $658,000 after buying an additional 4,738 shares in the last quarter. Finally, Deutsche Bank AG raised its position in AstraZeneca by 3.8% in the 4th quarter. Deutsche Bank AG now owns 164,624 shares of the company's stock worth $10,786,000 after purchasing an additional 6,039 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. UBS Group raised shares of AstraZeneca from a "neutral" rating to a "buy" rating in a research note on Thursday, February 13th. Morgan Stanley assumed coverage on shares of AstraZeneca in a report on Wednesday, February 12th. They set an "overweight" rating on the stock. Finally, BNP Paribas initiated coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective on the stock. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $88.00.

AstraZeneca Trading Down 2.2%

NASDAQ:AZN opened at $66.23 on Thursday. The firm's fifty day moving average is $70.73 and its 200-day moving average is $69.57. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The firm has a market cap of $205.40 billion, a P/E ratio of 29.31, a P/E/G ratio of 1.42 and a beta of 0.40.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. The business had revenue of $13.59 billion during the quarter, compared to analysts' expectations of $13.71 billion. During the same period last year, the company posted $2.06 earnings per share. The business's quarterly revenue was up 7.2% on a year-over-year basis. Equities analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.